DMAC Stock Overview
A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DiaMedica Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$4.95 |
| 52 Week Low | US$2.14 |
| Beta | 1.46 |
| 11 Month Change | 7.06% |
| 3 Month Change | 18.99% |
| 1 Year Change | 79.39% |
| 33 Year Change | 29.48% |
| 5 Year Change | 57.72% |
| Change since IPO | -85.94% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Nov 23
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
May 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 12FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
Jul 06We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Jun 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 04DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Nov 05DiaMedica: Undercovered Stroke Drug Company With Decent Data
Jun 13We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
May 01Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?
Feb 13
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn
Jan 09DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Shareholder Returns
| DMAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.3% | 2.5% | 2.2% |
| 1Y | 79.4% | 16.1% | 31.6% |
Return vs Industry: DMAC exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: DMAC exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| DMAC volatility | |
|---|---|
| DMAC Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DMAC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DMAC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 19 | Rick Pauls | www.diamedica.com |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases.
DiaMedica Therapeutics Inc. Fundamentals Summary
| DMAC fundamental statistics | |
|---|---|
| Market cap | US$200.97m |
| Earnings (TTM) | -US$21.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.3x
P/E RatioIs DMAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMAC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.71m |
| Earnings | -US$21.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DMAC perform over the long term?
See historical performance and comparison